IBM enters the final stretch of August with a striking divergence between two short-interest signals: the headline short position has collapsed by nearly 40% over the past month, yet this week saw a modest 4% week-on-week rebuild — a small counter-trend that gives the lending data a slightly different texture than the price action alone would suggest.
The clearest message from the positioning data is that bears have been retreating, not pressing. Short interest as a percentage of free float now runs at 2.3% — roughly half the 3.7% level seen in mid-July. Borrow conditions reflect that retreat too: the cost to borrow has eased about 22% over the week to just 0.34%, close to its lowest recent level. More telling still is availability, which has loosened dramatically. With over 560 million shares available to borrow — representing more than 3,400% of current short interest — there is effectively no scarcity in the lending pool. That is among the most open borrow conditions IBM has seen in the past year; the 52-week low in availability stood near 1,267%, itself considered loose. Options positioning corroborates the relatively relaxed tone. The put/call ratio of 0.80 is only modestly above its 20-day average of 0.78, barely two-thirds of a standard deviation from the mean. There is no meaningful hedging premium being paid here.
The Street picture is less clean than the positioning story, and the direction of recent analyst moves has been mostly down. After IBM's July 22 earnings — where the stock fell about 1.8% the next session before recovering 7.6% over the following five days — a cluster of firms trimmed targets sharply. Morgan Stanley cut to $190 from $293, keeping an Equal-Weight rating. Susquehanna dropped to $225 from $303, maintaining Neutral. Barclays brought its target to $262 from $350, though it kept an Overweight. Several other names including Jefferies, Stifel, and BMO made similar downward adjustments without changing their positive or neutral ratings. The consensus mean target now stands near $245 — about 4% above the current price of $235.59. The overall analyst split is a clean ten buy, ten hold, and no sells, which reads more as polite agnosticism than genuine conviction in either direction. Factor scores reinforce the mixed picture: the dividend score ranks in the 99th percentile, a rare signal of income quality, while forward EPS growth momentum sits in the bottom quartile, and analyst recommendation dispersion scores at just 7 — deeply below consensus relative to peers.
Institutional ownership tells a broadly constructive story. BlackRock holds 8.1% of shares and added a small position in its most recent filing. Vanguard entities collectively control well over 10% and have been adding incrementally. State Street added 1.45 million shares in the most recent period. These are index-linked flows more than active conviction, but the direction is net positive and no top-ten holder shows a significant trim. The ORTEX short score of 31.9 — low in absolute terms and barely changed over the past two weeks — is consistent with a stock where short sellers see no urgent catalyst, neither pressing a thesis nor rushing to cover.
The next earnings date is October 21. IBM's last two prints produced a one-day drop followed by a five-day recovery, a pattern that has kept active short sellers cautious about holding across the event. With availability still wide open, borrow costs minimal, and the short score subdued, the market into that date is one worth watching for any change in the rebuilding trend that appeared this week — whether it continues, reverses, or stalls will frame how much conviction either side brings into the Q3 release.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
